Skip to main content

Table 3 Analysis of efficacy

From: Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases

Efficacy measure All patients (n = 50)
Objective response, n (%) 36 (72)
   Complete response 2 (4)
   Partial response 34 (68)
Stable disease, n (%) 10 (20)
Progressive disease, n (%) 4 (8)
Mean overall survival, months (95% CI) 38.0 (32.65 to 43.35)
Median recurrence-free survival, responders; mts (95% CI) 24.73 (4.50 to 44.97)